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Abstract
Celiac disease, also known as “celiac sprue”, is a chronic 
inflammatory disorder of the small intestine, produced 
by the ingestion of dietary gluten products in susceptible 
people. It is a multifactorial disease, including genetic 
and environmental factors. Environmental trigger is 
represented by gluten while the genetic predisposition 
has been identified in the major histocompatibility 
complex region. Celiac disease is not a rare disorder like 
previously thought, with a global prevalence around 1%. 
The reason of its under-recognition is mainly referable to 
the fact that about half of affected people do not have 
the classic gastrointestinal symptoms, but they present 
nonspecific manifestations of nutritional deficiency or 
have no symptoms at all. Here we review the most 
recent data concerning epidemiology, pathogenesis, 
clinical presentation, available diagnostic tests and 
therapeutic management of celiac disease.
Key words: Celiac disease; Epidemiology; Diagnosis; 
Treatment; Pathogenesis
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Celiac disease is a chronic inflammatory 
disorder of the small intestine, produced by the 
ingestion of dietary gluten products in susceptible 
people. It is a multifactorial disease, including genetic 
and environmental factors. Thanks to advanced under-
standing of its pathogenesis, numerous therapeutic 
strategies have been devised for the treatment of celiac 
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disease. But there is need of further basic research 
studies and randomized clinical trials to introduce them 
into usual management of this disease.
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INTRODUCTION
Celiac disease defined an autoimmune disorder 
originating by an aberrant adaptive immune response 
against gluten-containing grains in susceptible indivi-
duals. Celiac disease was first described in 1888 by 
Samuel Gee, but only in 1953 it became clear the 
importance of the gluten in the origin of this patho-
logy[1-3]. In celiac subjects the ingestion of gluten leads 
to an enteropathy with an impairment of the mucosal 
surface and, consequently, abnormal absorption of 
nutrients[4-7]. Celiac disease might be considered a 
syndrome, because of the wide spectrum of clinical 
manifestations and the involvement of various human 
systems. Celiac disease shows peculiar features in 
comparison to others autoimmune disorders, including 
the complete recovery of the mucosal damage as well as 
the reversibility of its progression and chronic dynamics, 
with a total avoidance of gluten. Conversely, it is now 
ascertained that undiagnosed celiac disease, might 
have severe consequences in children as well as in adult 
subjects[8-10]. Besides celiac disease and wheat allergy, a 
new entity has been included, apparently not driven by 
an immune response: The non-celiac gluten sensitivity 
(NCGS). The pathogenesis of NCGS remains largely 
unknown, although it is now ascertained that it includes 
a set of factors[3,11]. Here, we review the epidemiology, 
pathogenesis, clinical presentation, diagnostic tests and 
therapeutic management of celiac disease. 
EPIDEMIOLOGY
In the last decades a high number of epidemiological 
data have been reported. Nowadays celiac disease is 
one of the most frequent genetically based disorder in 
humans, although it was thought that some country, 
including United States, were exempt from this dis-
ease[12]. Europe is historically considered a geographical 
area at high frequency, with a prevalence of 1%-2%, 
although it has been recently shown a similar prevalence 
in United States[13,14]. Despite the advances in diagnosis, 
the overall prevalence of this disease remains still 
unclear. A variable frequency has been reported between 
European countries, although it is still uncertain whether 
it depends on the different screening tool, sample size 
or a real variability of celiac disease prevalence[15]. What 
is known is that many cases remains undiagnosed, 
as idealized with the “iceberg model” (Figure 1). 
Typical cases of celiac disease are diagnosed because 
of suggestive symptoms. The submerged part of 
the iceberg represents all the undiagnosed cases 
that usually show atypical, minimal, or even absent 
symptoms[16]. A multicenter study reported a prevalence 
of 1 out of 133 (0.75%) in healthy people in the United 
States, and similar frequency is confirmed by studies 
on European and Australian populations[12]. The overall 
prevalence of celiac disease ranges from 4.5% among 
high-risk subjects to 0.75% in not-at-risk subjects[12]. 
High-risk subjects include the relatives of patients with 
celiac disease, children or adults with celiac disease-
associated symptoms (i.e., diarrhea, abdominal pain 
and constipation) and children or adult subjects with 
celiac disease-associated disorders (i.e., Diabetes 
Mellitus type-1, Down syndrome, anemia, infertility, 
osteoporosis)[17]. It has been shown that celiac disease 
is not exclusive of industrialized countries, but includes 
North Africa, Middle East and India with an incidence 
overlapping those of European countries[18-20]. However, 
given the worldwide distribution of the causal factors this 
heterogeneous diffusion is not surprising. It has been 
shown that the Saharawi, an Algerian population has the 
highest prevalence of celiac disease (nearly, 6%) among 
all of the worldwide populations[16,21,22].
GENETIC SUSCEPTIBILITY
The best-characterized genetic risk factor for celiac 
disease, accounting for 35% of the total genetic risk, 
is the presence of genes encoding for MHC class II 
proteins including human leukocyte antigen (HLA) DQ 
2 and HLA-DQ8[23-25]. Over 90% of affected subjects 
express HLA-DQ2 molecules; the remainder express 
HLA-DQ8. The frequency of celiac disease risk HLA 
genotypes is about 30%, whereas only 1%-3% 
develops the disease[26]. It is now accepted that HLA 
is one of the main but not sufficient factors involved in 
the onset of celiac disease, but a multitude of genetic 
factors are responsible in celiac disease susceptibility, 
as demonstrated by studies on monozygotic twins[27]. 
Recently, genome-wide association studies have 
identified 39 non-HLA loci that also predispose to celiac 
disease[28]. One of these genes may relate to genetic 
variants on chromosome 19, in the myosin IXB gene (i.e., 
MYO9B), and may potentially predict responsiveness 
to a gluten-free diet (GFD)[29,30]. Both HLA-DQ2 and 
HLA-DQ8 codified for heterodimers located on Antigen-
Presenting Cells (APCs)[31]. It has been ascertained 
that they present gluten peptides to antigen-specific 
T-lymphocytes in the intestinal mucosa, inducing their 
proliferation as well as cytokine production. In particular, 
tTG2 may transform non-charged glutamine into nega-
tively charged glutamic acid[32].
Environmental factors
Feeding patterns in the first year of life and potential 
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viral infections (i.e., rotavirus)[33] might be involved in 
the development of celiac disease[34]. A prospective 
study has investigated the role of a specific infectious 
agent in celiac disease and the authors have found 
that an increased frequency of rotavirus infection 
predicts increased risk of celiac disease autoimmunity in 
children[35]. Gluten, one of the most common ingredients 
in human nutrition[36], is mainly composed by prolamines 
and glutenin. The prolamines in wheat are gliadins, 
in rye secalines and in barley hordeins. Catassi et 
al[37] proposed that 50 mg gluten/day is the minimum 
amount able to determine evident alterations to the 
small-intestinal mucosa in celiac disease subjects. Others 
pivotal “environmental factors” as the milk-feeding 
type and the duration of breast-feeding, can also play 
a role, influencing the intestinal microenvironment[38]. 
In addition, increased intestinal Gram-negative and 
reduced Bifidobacteria, has been found in celiac disease 
subjects[39]. Other debated environmental factors could 
be represented by heavy metals[40] and bacterial TG 
present in food stuff[41]. 
IMMUNE SYSTEM AND THE CELIAC 
DISEASE
Celiac disease resembles a systemic immune-mediated 
disorder[34,42-44]. The primary mechanism involved in 
celiac disease is related to an inappropriate adaptive 
immune response to gluten-derived peptides. It has 
been ascertained that prolamines contain critical 
epitopes presented by either HLA-DQ2 or HLA-DQ8 
induce a CD4+ T-lymphocytes response. In celiac 
disease pathogenesis the role exerted by the intestinal 
epithelia barrier, physiologically impermeable to macro-
molecules such as gliadin is actually recognized. In 
people with a genetic susceptibility to develop celiac 
disease, gliadin interacts with the intestinal cells to 
trigger the disassembling of the inter-enterocyte tight 
junctions (TJs). The impairment of the TJs determines 
the up-regulation of zonulin, a peptide involved in 
TJ regulation and responsible for the increased gut 
permeability. Gliadin peptides pass through the epithelial 
barrier and activate T-lymphocytes located in the 
lamina propria. Activated CD4+ T-lymphocytes produce 
high levels of pro-inflammatory cytokines, inducing 
either a T-helper 1 pattern dominated by IFN-γ, and 
a T-helper 2 pattern, which causes a clonal expansion 
of B-lymphocytes that subsequently differentiate in 
plasma-cells secreting anti-gliadin and anti-tissue-
transglutaminase antibodies[45]. Some gliadin peptides 
that are not recognized by T-lymphocytes activate 
both APCs and intestinal epithelial cells; in particular, 
CD8+ T-lymphocytes may be stimulated by interleukin 
(IL)-15. An increased density of CD8+ intraepithelial 
cells is considered as a hallmark of celiac disease[34]. 
Gliadin-specific T-cell responses have been found to be 
enhanced by the action of tissue transglutaminase, an 
enzyme located in the extracellular space of the sub-
epithelial region or at the epithelial brush border[46]. 
HISTOLOGICAL FEATURES OF THE 
CELIAC DISEASE
Physiologically the height of enterocytes ranges 
between 29-34 μm. T-cells are usually located in the 
lamina propria; however, the number of intraepithelial 
lymphocytes (IELs) is highly variable. A large number of 
subjects without disease have less than 20 lymphocytes 
per 100 epithelial cells; based on the experiences of 
Hayat et al[47] and Veress et al[48], a density of IELs 
between 25 and 29/100 epithelial cells is considered 
borderline and pathological over 30/100 epithelial cells.
Tissue samples taken from subjects affected by celiac 
disease mainly show: (1) Decreased enterocyte height; 
(2) Crypt hyperplasia; (3) Villous atrophy; (4) Increased 
intraepithelial T lymphocytes.
Although still debated, recently, Mubarak et al[49] 
have shown that staining for CD3 has an additional 
value in the histological detection of celiac disease le-
sions[49,50]. Immunohistochemical stains for CD3 and 
CD8 do not improve detection of gluten-sensitive enter-
opathy in duodenal biopsies. A different grading has 
been proposed for the evaluation of the gluten free diet 
in duodenal mucosal healing[51].
Table 1 reports Marsh classification of histologic 
findings in celiac disease[52]. Modifications to this scoring 
system have been proposed[53,54]. Oberhuber et al[55] 
suggested that Marsh III lesions should be included into 
a, b, and c categories. However, Figure 2 shows two 
prototypical tissues classified as Marsh II (A) and Marsh 
IIIA (B). 
CELIAC DISEASE: CLINICAL 
PRESENTATION
Celiac disease is greatly heterogeneous, at least in 
part depending on the patient’s age, the duration and 
extent of disease, and the presence of extra-intestinal 
comorbidities.
Although celiac disease was originally thought as a 
pediatric disorder, the diagnosis is increasingly made in 
adults[16]. Various subtypes of celiac disease have been 
described[56]. 
Classical or typical form. It is characterized by 
common clinical symptoms related to abnormal intestinal 
absorption. Generally occurs between 6 and 18 mo of 
age, after the introduction of weaning foods containing 
prolamines[57]. Histology shows villous atrophy and crypt 
hyperplasia.
Atypical form
It is characterized by a prevalence of extra-intestinal 
symptoms with few or no gastrointestinal symptoms. 
Usually, atypical forms are encountered in older children 
and adults and the common features of abnormal 
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absorption are absent.
Silent or asymptomatic form
It is characterized by serological and histological 
abnormalities without evidence of clinical symptoms. 
This subtype is often observed in subjects with a family 
history of celiac disease, patients with associated 
autoimmune (i.e., type 1 diabetes) or genetic disorders 
30 May 15, 2017|Volume 8|Issue 2|WJGP|www.wjgnet.com
  Marsh 0 Normal mucosal architecture without significant intraepithelial lymphocytic infiltration.
  Marsh I Lymphocytic enteritis: Normal mucosal architecture with a marked infiltration of villous epithelium by lymphocytes; arbitrarily defined 
marked as more than 30 lymphocytes per 100 enterocytes
  Marsh II Lymphocytic enteritis with crypt hyperplasia: intraepithelial lymphocytosis and elongation and branching of crypts in which there is an 
increased proliferation of epithelial cells
  Marsh III Intraepithelial lymphocytosis, crypt hyperplasia, and villous atrophy. There are 3 distinct stages of villous atrophy
     Marsh IIIA Partial villous atrophy, the villi are blunt and shortened. Arbitrarily, samples are classified as partial villous atrophy if the villus-crypt 
ratio was less than 1:1
     Marsh IIIB Subtotal villous atrophy, villi are clearly atrophic, but still recognizable
     Marsh IIIC Total villous atrophy, villi are rudimentary or absent, and the mucosa resemble colonic mucosa.
Table 1  Marsh classification of histologic findings in celiac disease
Modifications to this scoring system have been proposed[53,54]. Oberhuber et al[55] suggested that Marsh III lesions should be included into a, b, and c 
categories. However, Marsh et al[52] examined these subdivisions by means of correlative light and scanning electron microscopy, and demonstrate that 
Oberhuber’s classification is untenable. In their view, this categorization reflects misinterpretations of the real architectural contours of flat mucosae.
Symptomatic
celliac disease
Silent
celiac disease
Latent
celiac disease
Damaged intestinal
villi
Natural intestinal
villi
Figure 1  The “iceberg model” idealizing the interplay between celiac disease genetic makeup and exposure to gluten, the environmental trigger of the 
disease.
A B
Figure 2  Histological features of celiac disease. A: Example of tissue scored as Marsh 2 characterized by lymphocytic enteritis with crypt hyperplasia: 
Intraepithelial lymphocytosis and elongation and branching of crypts in which there is an increased proliferation of epithelial cells; B: Example of tissue scored as 
Marsh 3A characterized by partial villous atrophy, the villi are blunt and shortened. Arbitrarily, samples are classified as partial villous atrophy if the villus-crypt ratio 
was less than 1:1 (Objective magnification × 4, inset × 10).
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(i.e., Down, Turner, or Williams syndrome). 
Latent form
It is characteristic of subjects with previous asympto-
matic celiac disease, although a gluten-containing 
diet. Positive serology but no villous atrophy or others 
tissue abnormalities are recognized. Troncone et al[58] 
postulated that the presence of elevated endomysial 
antibodies in these patients might be one of the most 
important predictor of progression.
Potential form
The term “potential” is used in individuals who have 
never had diagnosis of celiac disease, but show pre-
sence of appropriate genetic background (HLA-DQ2/
DQ8), positive serology, with normal or mildly abnormal 
histology. 
Refractory form
It is defined by the presence of malabsorptive sym-
ptoms and villous atrophy that persist 1 year after 
a strict gluten-free diet. Several refractory patients 
(roughly, 5%-30%) never respond to a gluten-free 
diet[59], others initially responded but have a recurrence 
of symptoms and intestinal damage. Two different sub-
types of refractory celiac disease have been recognized: 
“Type 1”, showing a normal intraepithelial lymphocytes 
count and “type 2” presenting aberrant intraepithelial 
lymphocytes[29].
Celiac disease can affect individuals from any age, 
but two peaks can be seen: In the childhood (< 6-year-
old) and 4th-5th decade[46]. Classical presentation is more 
frequent in pediatric and tends to occur early in life (6-24 
mo), whereas atypical presentation generally occurs at 
a later age (> 5-year-old) and in adults[60].
DERMATOLOGICAL CELIAC DISEASE 
Dermatitis herpetiformis is an inflammatory cutaneous 
disease, presenting with diffuse, symmetrical, polymor-
phic lesions consisting of erythema, urticarial plaques, 
papules, herpetiform vesiculae and blisters followed 
by erosions, excoriations and hyperpigmentation. It 
is characterized by typical histopathological and immu-
nopathological findings. Rarely it is diagnosed in child-
hood but commonly appears in the third decade. 
MAIN CONDITIONS ASSOCIATED TO 
CELIAC DISEASE
A set of conditions can be associated with celiac disease. 
The term “associated conditions” refers to states that 
are found more frequently in patients affected by celiac 
disease[61]. These conditions include “genetic disorders” 
such as Down syndrome, Turner syndrome and Wil-
liams syndrome, and “autoimmune” or “neurological” 
disorders. 
Type 1-diabetes 
One of the most recognized and widely investigated 
disorders associated with celiac disease is type 
1-diabetes[62]. Ludvigsson et al[63] reported that type 
1-diabetes constitutes a 5- to 10-fold risk increase 
for celiac disease in a very large cohort of children. 
This increasing of risk may partly be explained by 
shared genetic risk represented by HLA. A percentage 
approximately of 5%-10% of patients affected by type 
1-diabetes presented celiac disease related antibodies 
with up to 75% having abnormalities on small intestinal 
biopsy tissue[64]. The prevalence of celiac disease ranges 
between 1% to 19% in patients with type 1 diabetes 
mellitus[65]. Prospective studies of high-risk infants for 
type 1 diabetes and celiac disease have been shown 
that early introduction of gluten is associated with 
an increased risk for autoimmunity[66-68]. However, 
the relationship between the two conditions is still 
debated[69]. 
Autoimmune thyroid disorders 
In patients affected by celiac disease it has been 
reported an increased prevalence (nearly, 2%-5%) of 
thyroid disorders (i.e., hyperthyroidism-Graves’s disease 
or hypothyroidism-Hashimoto’s thyroiditis), diagnosed 
either before than after the diagnosis of gluten-enter-
opathy[65]. These two conditions share genetic risk 
factors represented by HLA-DQ2 and DQ8. HLA-DQ2 
and DQ8 haplotypes have been association with Hashi-
moto’s thyroiditis, while HLA-DQ2 association is less 
clear in Graves’ disease. This difference between hyper- 
and hypothyroidism is reflected also by the greater risk 
of celiac disease in patients with Hashimoto’s disorder 
than patients with Graves[70]. In addition to HLA, it has 
been reported an association with the gene encoding 
cytotoxic T-lymphocyte-associated antigen-4[65]. Another 
mechanism related to the association between these 
two conditions is represented by abnormal absorption 
with consequent selenium deficiency induced by celiac 
disease. Stazi et al[70] highlighted that the abnormal 
selenium absorption in celiac disease could be the factor 
directly leading to thyroid and intestinal damage, since 
thyroid is particularly sensitive to selenium deficiency. 
In the setting of autoimmune thyroid disease it should 
be useful to pay attention to celiac disease marker and 
to monitor growth and pubertal status. In patients with 
celiac disease, a screening for thyroid abnormalities has 
been also suggested in some cases[61].
Autoimmune hepatitis and other forms of liver 
involvement 
The involvement of liver is common among patients 
affected by celiac disease[71]. Hypertransaminasemia 
has been reported in about 40% of adults and in 
54% of children with a classical presentation of celiac 
disease at the time of diagnosis[72]. Conversely, celiac 
disease is present in about 9% of patients with chronic 
unexplained hypertransaminasemia[73,74]. It has been 
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postulated that the mechanism leading to hepatic 
damage is related to entry of toxins, inflammatory 
molecules and antigens in the portal circulation. Volta 
et al[75] pointed up about the need of a serological 
screening for celiac disease in all patients with persistent 
hypertransaminasemia of unknown cause. Moreover, 
exclusion of a gluten-related liver damage is necessary 
for all patients affected by autoimmune liver disorders 
or by those forms of severe liver disease, whose 
etiology remains unknown, and for patients enrolled for 
liver transplant. A prolonged exposition to gluten in a 
patient with an overlooked celiac disease, in fact, can 
causes chronic hepatitis and liver cirrhosis[75,76].
Neurological disorders 
It has been reported a potential link between celiac 
disease and different neurological disorders[77]. Data 
concerning the association between neurological condi-
tions and celiac disease remain poor. Although ataxia 
is a neurological disorder indicated in some patients 
with celiac disease[78], the most frequent neurologic 
condition in celiac disease subjects is epilepsy, showing 
a prevalence between 1.2% and 5%[79]. Its clinical 
spectrum in association with celiac disease varies from 
focal to generalize with variable outcome and response 
to gluten avoidance. In 1985 it has been described a 
more specific and rare syndrome characterized by the 
co-presence of celiac disease, epilepsy, and occipital 
calcifications (CEC). Gobbi suggested that the HLA geno-
type predisposing to CEC is the same to that predispose 
to celiac disease[79].
COMPLICATIONS ASSOCIATED WITH 
UNTREATED CELIAC DISEASE 
Evidences that celiac disease in adults, especially if 
diagnosed late is burdened by complications have been 
reported. Among them: (1) Osteoporosis: It represents 
the most common complication resulting from abnormal 
calcium absorption secondary to defective calcium 
transport by the diseased small intestine, but also due 
to vitamin D deficiency. With an early gluten free diet 
in children it is possible to prevent the bone disease in 
adult life; (2) Enteropathy-associated intestinal T cells 
lymphoma: It represents one of the most important 
complication; (3) Collagenous sprue: Patients do not 
react to diet and histology shows extra-cellular matrix 
components in the intestinal wall at the level of the 
superficial sub-epithelial layer. This morphological 
pattern is very similar to the condition of collagenous 
colitis described in the colon, where the thickness of 
the connective band best highlighted with Masson’s 
trichrome is more than 15 nanometers, although this is a 
very rare event described in the literature; (4) Refractory 
sprue: This condition is depicted as collagenous sprue 
although can be identified by immunohistochemical 
staining, demonstrating that T lymphocytes, which in 
normal conditions express CD3 and CD8, in this case 
present only the expression of CD3 and not of CD8; 
(5) Ulcerative jejunoileitis: Extensive ulceration of the 
intestinal mucosa, and involving ileum and jejunum. 
It presents around 50 years old with chronic diarrhea, 
steatorrhoea and complications of intestinal ulceration 
(perforation, haemorrhage or obstruction)[59]; (6) 
Non-Hodgkin lymphoma: Recent data suggests an 
association between celiac disease and Non-Hodgkin 
lymphoma[80]; (7) Small bowel adenocarcinoma: Even 
rare, a connection between carcinoma of the small bowel 
and celiac disease is known since 1958[81]. The etiologic 
factors predisposing to malignancy in celiac disease are 
uncertain. Possibilities include immunologic disturbance 
associated with mucosal lymphocyte infiltration, pre-
malignant changes in the damaged surface epithelial 
cells, increased permeability to oncogenic factors and 
abnormal absorption of protective substances such as 
vitamins A and E; and (8) Reproductive disorders: Celiac 
disease might be associated with decreased fertility in 
both males and females[82]. 
DIAGNOSTIC TESTS OF CELIAC DISEASE
Serological tests
Anti-tissue transglutaminase antibodies: the best 
strategy for serological diagnosis is the blood detection 
of IgA anti-tissue transglutaminase antibodies (tTGA) by 
enzyme-linked immunosorbent assay (ELISA). These 
antibodies show a sensitivity up to 97%, a specificity 
around 96%, and an accuracy of 98%, whereas IgA 
anti-endomysial (IgA EMA) antibodies are employed as 
a confirmatory test in tTGA positive cases due to their 
higher specificity (about 100% vs 91% of tTGA). In 
concomitance of IgA deficiency and celiac disease, found 
in around 2%-10% of the patients, it is recommended 
to detect celiac disease testing tTG-IgG. “False negative” 
occurs, as previously reported, in case of IgA defici-
ency. The IgA EMA represents the most specific test 
(approximately 100%), with a sensitivity around 94% 
and a diagnostic accuracy of 97%[83]. However, EMA 
are routinely detected by indirect subjective immuno-
fluorescence[84]. These antibodies can also result falsely 
negative in case of IgA deficiency and in children aged > 
2 years. 
Anti-gliadin antibodies: The antigliadin (AGA) 
antibodies (IgG and IgA) are today no longer recom-
mended because of their low sensitivity and specificity 
and inferior accuracy, except in younger children[85]. 
Deamidated gliadin peptides: Actually detection 
of antigliadin antibodies have been replaced by the 
more recently developed immunoassays employing 
antibodies to deamidated gliadin peptides, IgA and IgG. 
To increase the diagnostic accuracy, in the last years the 
clinicians tend to prescribe serial testing. 
Histology
The gold standard to diagnose celiac disease in adulthood 
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is the intestinal biopsy sampled by endoscopy[54,86]. 
Histology of celiac disease consists of an integrated 
assessment of different entities: villous atrophy, crypt 
hyperplasia, decreased enterocyte height, inflammatory 
infiltrates in small-bowel mucosal biopsies. Based on one 
or more of these elementary lesions the histopathology 
of celiac disease is subdivided into different diagnostic 
categories according to the Marsh classification[86] (Table 
1).
The open question remains the early lesions, i.e., 
normal villi with a pathologic increase in intraepithelial 
T-lymphocytes, that it is possible to find in many others 
conditions[87]. Villanacci et al[86] pointed out that three 
conditions deserve specific mention: (1) “Autoimmune 
enteritis”; (2) Damage by drugs: especially non-
steroidal anti-inflammatory drugs (NSAID) that cause 
morphological modifications likely to those of celiac 
disease; and (3) The co-infection with Helicobacter 
pylori in the stomach[86].
Recently, have been introduced methods to quantify 
pathologic features of the small intestinal mucosa in 
celiac patients[88]. 
Genetic analyses
HLA testing should not be routinely performed in all 
celiac disease cases, but it is indicated only when dia-
gnosis is controversial. Large multicenter studies have 
shown that only 0.4% of celiac disease patients are 
both DQ2 and DQ8 negative[89]. In the absence of 
HLADQ2/8, it is consented to rule out predisposition to 
celiac disease in family members of celiac patients[86]. 
HLA test represents a helpful tool particularly for 
potential celiac disease, to suggest (if positive) or 
reject (if negative) the diagnosis. Furthermore, HLA 
negativity in patients with villous atrophy and negative 
serology should direct towards other possible causes 
of these histological alterations. Many disorders, such 
as lactose intolerance, bacterial overgrowth, Cro-
hn’s disease, infectious diseases (i.e., Giardia lamblia, 
Cryptosporidium, Microsporidium, Cytomegalovirus, 
Herpes virus, Whipple’s disease), characterized by mal-
absorption share the same histological findings as celiac 
disease. 
In vitro gluten challenge test
Currently, several studies have proposed that gluten-
sensitive immunological activation in celiac disease can 
be reproduced by in vitro gluten challenge test using 
culture cells from the duodenal mucosa[90]. 
CURRENT TREATMENTS OF CELIAC 
DISEASE
Life-long gluten-free diet
The current available treatment for celiac disease is life-
long gluten-free diet[91-93]. Generally clinical improvement 
is achieved within a few weeks and the mucosal damage 
recovers in 1-2 years[16]. As patients with celiac disease 
may have accompanying brush border lactase deficiency 
secondary to damage to surface epithelial cells, milk 
and dairy products should be avoided in the first period 
of treatment too. As vitamin B deficiency is common 
after an extended period on a GFD, all patients are 
advised to take a gluten-free multivitamin[84]. Early 
diagnosis and treatment are fundamental in pediatric 
celiac disease particularly, as some of the complications 
may be irreversible: Growth retardation, abnormal 
dentition, osteoporosis[29]. Several observational studies 
suggest that prolonging breast-feeding and delaying 
and gradually introducing gluten in the first year of 
life may reduce the risk of celiac disease development 
during childhood[60]. As described above, even products 
specifically targeted to dietary treatment of celiac disease 
may contain tiny amounts of gluten proteins[16]. Another 
cause of uncertainty is represented by the differences 
in the labeling rules for food products existing among 
countries. Specific considerations about gluten free diet 
and refractory celiac disease should be taken. Even with 
respect of dietary restriction, actually, in the minority of 
patients affected by refractory celiac disease (RCD), GFD 
is ineffective. It has showed a higher mortality compared 
with RCD type 1, explainable by the more severe 
malnutrition combined with the higher risk of developing 
overt lymphoma[94]. These forms of the disease can 
require corticosteroids and other immunosuppressant, 
like azathioprine or cyclosporin, which can improve 
transiently clinical symptoms in most patients. But till 
date, it has not yet been possible to design effective 
treatments for the both form of RCD[94]. Furthermore, it 
is important remember that these drugs may enhance 
the risk of progression into an overt T-cell lymphoma, so 
they require caution particularly in RCD type 2 patients, 
at risk of developing this complication. Recently, have 
been used with some success chemotherapy agents 
such as the anti-T cell nucleoside analogues Cladribine 
and Pentostatine, and it has been proposed also as a 
therapeutic option the stem cell transplantation[95,96].
Other drug-based therapies are in under investi-
gations although patients indicate GFD as a good and 
well-tolerated therapy[97,98].
Gluten-degrading enzymes
Enzyme supplement therapy with bacterial prolyl-
endopeptidasis expressed by various microorganism 
has been proposed to accelerate gluten digestion in 
the gastrointestinal tract and thus to destroy T cell 
epitopes[99]. Prolyl-endopeptidasis are proline-specific 
enzymes capable to cleave gluten peptides. Actually, 
there are introduced into clinical trials two drug 
candidates, ALV003 and AN-PEP (Aspergillus niger 
prolyl-endoprotease). Recent data on results of two 
phase 1 clinical trials have revealed that pre-treating 
gluten with ALV003 eliminates the peripheral blood T 
cell response in celiac disease patients, suggesting the 
potential therapeutic utility of gluten-specific enzymes to 
treat celiac disease[100]. Currently is undergoing clinical 
phase IIa testing showing a significantly reduce gluten-
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related T-cell responses compared with placebo but 
without a significantly reduction of symptoms typically 
induced by the gluten[101].
AN-PEP is an enzyme that degrades gluten pep-
tides efficiently in a pH compatible with that found in 
the stomach. Therefore this enzyme might be suitable 
for oral supplementation but further studies are ne-
cessary[102]. 
Modified grains 
Can be developed either through selective breeding 
of early wheat species or using small interfering RNA 
(siRNA) technology to mutate or silence immunos-
timulatory sequence[103].
Blocking gluten entry across the intestinal epithelium 
Zonulin inhibitor larazotide (AT-1001) corrects intestinal 
barrier defects. It has been explored in an animal 
model[99]. AT-1001 is currently the best-studied pharma-
cologic agent to treat patients with celiac disease, 
actually undergone in phase II clinical trials[104]. It 
has been shown that patients treated with AT-1001 
had an improved symptom score, a less pronounced 
autoantibody response and pro-inflammatory production, 
and lower urinary nitrate excretion when compared with 
the placebo controls[105].
Rho/Rho kinase inhibition
It has been clarified that the increase in intestinal per-
meability is dependent on Rho kinase (ROCK) activity[106]. 
In addition to regulating tight junction structure and 
function, ROCK is known to regulate axon growth[107,108]. 
The drug could be used to establish whether ROCK 
inhibition can reverse gluten-dependent increase in 
intestinal permeability in these patients[104].
Immunotherapy
The first observation of the occurrence of celiac disease 
following allogenic bone marrow transplantation per-
formed in a patient with acute leukemia, made evident 
the involvement of T-lymphocyte in pathogenesis of this 
condition[109]. Since then, a lot of acknowledgments have 
been acquired such that many efforts are being made 
to develop immunologic therapeutic tools. Cytokine 
therapies based either on amplification of regulatory 
cytokines or on blockage of inflammatory cytokines 
expression are largely diffused for management of 
the severe autoimmune disorders. Also for celiac dis-
ease resistant to dietary approach and especially for 
refractory celiac disease, the use of immunomodulators 
is developing. IL-15 blocking antibodies have shown 
the capability to induce intra-epithelial lymphocytes 
apoptosis in the intestinal epithelium of human IL-15 
transgenic mouse models[110]. These antibodies have 
been only investigated on patients with rheumatoid 
arthritis and a human study for celiac disease is still 
awaited. Only human recombinant IL-10 was tried and it 
showed suppression of gluten-dependent T-cell activation 
in celiac disease cultured intestinal mucosa[111]. But later, 
a pilot study conducted on patients affected by refractory 
celiac disease did not show any pharmacological efficacy 
of this monoclonal antibody[110]. Anti-IFN-γ antibodies 
demonstrated a good tolerance among patients with 
inflammatory bowel disease, but the use in patients 
with celiac disease needs of more investigations. Equal 
considerations can be assumed also for the use of 
antibodies anti-TNF-α, commonly recognized for the 
treatment of inflammatory bowel disease but described 
only in few case reports of patients with refractory celiac 
disease[112,113]. Another possible target of immunotherapy 
is represented by chemokines and their receptors, 
which play a significant role in the pathogenesis of celiac 
disease through the recruitment of lymphocytes in the 
gut. T-lymphocytes that home to the small intestine 
express CCR9, which binds to the CCL25 secreted by 
intestinal epithelial cells, and integrin α4β7, which binds 
to mucosal vascular addressin cell 1 (MAdCAM-1). 
Therefore both molecules are necessary for migration 
of T-cells to the intestinal mucosa and could represent 
potential therapeutic targets. Furthermore, a monoclonal 
antibody anti-integrin α4 (Natalizumab) has revealed 
effectiveness in Crohn’s disease suggesting a possible 
effectiveness also in celiac disease[114] as well as a CCR9 
inhibitor (CCX282-B) and integrin α4β7 blocking antibody 
(LDP-02), both already studied in patients affected by 
Crohn’s disease but still under investigation for celiac 
disease[115]. Some concern could be raised about the 
benefit of blocking lymphocyte homing to the intestine, 
and potential long-term adverse consequences, also 
because beneficial immunosuppressive regulatory T 
cells are equally inhibited. Since its demonstration, 
the possibility to develop tolerance to gluten in certain 
patients affected by celiac disease has gained more 
attractiveness as another potential immunomodulatory 
approach[116,117]. An alternative method studied for 
induction of tolerance to gluten is oral administration of a 
genetically modified Lactococus lactis bacterium, capable 
of secreting deamidated DQ8-restricted gliadin epitope. 
This experiment was conducted on previously sensitized 
transgenic mice and demonstrated the induction of 
Foxp3+ regulatory T-lymphocytes and a significant 
suppression of local and systemic T-cell responses 
to the corresponding gliadin peptide[104,118]. Also this 
approach still needs of human trials, although others 
clinical trials for non-specific immunomodulation have 
been carried out to test the role of parasitic infection 
in inhibition of immune response to gluten[119]. In fact, 
the disappearance of intestinal parasites from humans 
in developed countries has created a predisposition to 
develop autoimmune disease, a phase I clinical trial 
using larvae from the hookworm Necator Americanus 
has been initiated with the purpose of establishing a 
potential shift of T-cells response toward a suppressive 
T-regulatory response, however to date, any significant 
effect was revealed by this infection on gluten-induced 
enteropathy[120].
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Vaccines
Clinical trials have been started with a prototypical 
vaccine based on a set of gluten peptides that are recog-
nized by HLA-DQ2 in an immunodominant manner[104], 
and phase I has been recently completed. A great 
interest is focused on vaccination, especially for raising 
the compliance of many patients which could beneficiate 
with a single-dose administration rather than a daily 
intake of other treatment options[110]. The risk of immune 
system activation related to the vaccine therapy and its 
side effects represent a still open question that need of 
further investigations. There is still need of more studies 
also for the most part of the previously mentioned 
alternative treatment options, with large long-term 
clinical trials that could answer to the unresolved ques-
tions relating to their real clinical effectiveness, their 
safety, and their affordability.
CONCLUSION
It is indubitable that celiac disease remains a still 
controversial and complex human disorder. There 
is need of further research studies and randomized 
clinical trials to introduce them into usual management 
of this disease. A number of unanswered questions 
remain to clarify including the real associations of 
celiac disease with other conditions, and the impact of 
some environmental factor in its pathogenesis. There 
are still controversial opinion about the effective role 
of the breast feeding in celiac disease, what is to be 
elucidated if it could offer a permanent protection or if 
only delays the appearance of the disease. In addition, 
an improvement in non-invasive diagnostic tests could 
allow avoidance of endoscopy, especially in pediatric 
patients, and a more defined efficacy of the new 
therapeutic tools could improve quality of life either in 
term of reduction of complications and physical health 
either in term of social life. 
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